A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a phase 2, open-label study to evaluate the safety, tolerability and efficacy of Irpagratinib in combination with Atezolizumab and Bevacizumab in patients with advanced or unresectable HCC harboring FGF19 overexpression. This study composes two parts, a Safety Run-in part to evaluate safety and establish the dose of Irpagratinib for the triple combination, and an Expansion part to evaluate the preliminary efficacy and safety using Simon's two-stage design.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 19 lat
- •Potwierdzony rozpoznanie zaawansowanego raka wątroby, którego nie można operować
- •Posiada pozytywy wynik testu na nadmiar białka FGF19 w próbce tkanki
- •Ogólny stan zdrowia pozwalający na udział w badaniu (ECOG 0-1)
- •Spodziewana długość życia co najmniej 3 miesiące
- •Prawidłowe wyniki badań krwi (liczba białych krwinek, płytki krwi, hemoglobina, wątroba, nerki)
Simplified criteria — AI translation
Trial details
- Minimum age
- 19 Years
- Last updated (source)
- July 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Asan Medical Center,
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Trial contact
Changhoon Yoo
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.